Goldman Sachs’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-196,365
| Closed | -$400K | – | 6936 |
|
|
2021
Q3 | $400K | Sell |
196,365
-205,932
| -51% | -$479K | ﹤0.01% | 5333 |
|
|
2021
Q2 | $1.2M | Buy |
402,297
+360,299
| +858% | +$951K | ﹤0.01% | 4626 |
|
|
2021
Q1 | $116K | Buy |
41,998
+18,975
| +82% | +$57.3K | ﹤0.01% | 5801 |
|
|
2020
Q4 | $56K | Sell |
23,023
-9,280
| -29% | -$22.4K | ﹤0.01% | 5369 |
|
|
2020
Q3 | $68K | Buy |
32,303
+294
| +0.9% | +$991 | ﹤0.01% | 5147 |
|
|
2020
Q2 | $121K | Buy |
32,009
+7,243
| +29% | +$21.7K | ﹤0.01% | 4947 |
|
|
2020
Q1 | $47K | Sell |
24,766
-9,474
| -28% | -$24.6K | ﹤0.01% | 5064 |
|
|
2019
Q4 | $71K | Buy |
34,240
+4,814
| +16% | +$9.23K | ﹤0.01% | 5091 |
|
|
2019
Q3 | $70K | Buy |
29,426
+1,387
| +5% | +$3.73K | ﹤0.01% | 5008 |
|
|
2019
Q2 | $88K | Sell |
28,039
-68,303
| -71% | -$251K | ﹤0.01% | 4946 |
|
|
2019
Q1 | $480K | Buy |
96,342
+77,004
| +398% | +$379K | ﹤0.01% | 4432 |
|
|
2018
Q4 | $87K | Sell |
19,338
-102,249
| -84% | -$499K | ﹤0.01% | 5019 |
|
|
2018
Q3 | $590K | Sell |
121,587
-266,808
| -69% | -$1.36M | ﹤0.01% | 4339 |
|
|
2018
Q2 | $2.33M | Buy |
388,395
+357,643
| +1,163% | +$2.62M | ﹤0.01% | 3533 |
|
|
2018
Q1 | $272K | Sell |
30,752
-6,793
| -18% | -$50.9K | ﹤0.01% | 4831 |
|
|
2017
Q4 | $272K | Buy |
+37,545
| New | +$235K | ﹤0.01% | 5239 |
|
Goldman Sachs's SBBP Position: Q4 2021 in Review
Goldman Sachs sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 196,365 shares — an estimated $400K sold.
Goldman Sachs first reported a position in SBBP in Q4 2017 and held it in 16 quarters. The position peaked at $2.33M in Q2 2018. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- Goldman Sachs reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- Goldman Sachs sold 196,365 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $400K.
- Goldman Sachs first reported a position in Strongbridge Biopharma plc. in Q4 2017 and held it in 16 quarters.
- Goldman Sachs's Strongbridge Biopharma plc. position peaked at $2.33M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.